IQVIA delivered second-quarter results at the high-end of our guidance, driven mainly by better-than-expected TAS performance. William Blair writes that IQVIA has underperformed so far in 2024 due to ...
The prices of US brand-name drugs grew more slowly from 2014–2019 than during the previous 5 years, and the slowdown is expected to continue through 2024, according to the ninth annual report on ...
Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s ...
IQVIA Holdings is positioned as the indispensable data and technology backbone of the life sciences industry, far beyond a traditional CRO. Long-term revenue visibility is underpinned by a record ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results